Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624471 | 0.89 | EP300 (0.47) | EP300MAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL3625401 | 0.78 | RORC (0.46) | MAPTTHRBRORCLMNA | |
| SCHEMBL3625398 | 0.78 | RORC (0.46) | MAPTTHRBRORCLMNA | |
| SCHEMBL3624234 | 0.77 | RORC (0.47) | RORC | |
| SCHEMBL12024511 | 0.72 | KMT2A (0.52) | MAPTSMN1; SMN2ALDH1A1GLAHPGD | |
| SCHEMBL3627243 | 0.71 | FAAH (0.43) | MAPTTHRBRORCLMNA | |
| SCHEMBL3627248 | 0.71 | FAAH (0.43) | MAPTTHRBRORCLMNA | |
| SCHEMBL3619476 | 0.68 | RORC (0.57) | ALDH1A1RORC | |
| SCHEMBL3623629 | 0.68 | RORC (0.43) | MAPTTHRBRORCLMNA | |
| SCHEMBL3623625 | 0.68 | RORC (0.43) | MAPTTHRBRORCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392567-A1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |